What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate - or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial

Lawrence, NJ; Martin, A; Davis, ID; Troon, S; Sengupta, S; Hovey, E; Coskinas, X; ... Stockler, MR; + view all Lawrence, NJ; Martin, A; Davis, ID; Troon, S; Sengupta, S; Hovey, E; Coskinas, X; Kaplan, R; Smith, B; Ritchie, A; Meade, A; Eisen, T; Blinman, P; Stockler, MR; - view fewer (2018) What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate - or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer , 2 (2) pp. 123-131. 10.3233/KCA-180038 . Green open access

http://bit.ly/2GyPFIW